LINC02518: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02518

NCBI ID: G105377957

LINC02518

Other Name(s): long intergenic non-protein coding RNA 2518 | Uncharacterized LOC105377957, transcript variant X2 | LOC105377957 variant X2

LINC02518: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Introduction

LINC02518 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified using RNA sequencing (RNA-seq) data. It is located between the genes P2R1A and PRKG2 and has a length of 295 nucleotides. The RNA-seq data has revealed that LINC02518 is expressed in various tissues and cells, including the brain, heart, liver, and muscle. It is also highly expressed in the placenta, which is a critical site for fetal development and growth.

The function of LINC02518 is not well understood, but it is possible that it plays a role in the regulation of gene expression. RNA-seq data has identified several putative binding sites in the RNA for proteins that could potentially interact with LINC02518. One of these proteins is the protein encoded by the gene USP4, which is a known regulator of gene expression. USP4 has been shown to interact with LINC02518 and can promote its expression in cell culture.

Another potential interaction with LINC02518 is the protein encoded by the gene HNIP1, which is also known to regulate gene expression. HNIP1 has been shown to interact with LINC02518 and can also promote its expression in cell culture.

In addition to these potential interactions, LINC02518 has also been shown to play a role in the regulation of microRNA (miRNA) expression. Express. LINC02518 has been shown to interact with several miRNAs, including miR-202 and miR-18a. These interactions may play a role in the regulation of gene expression and could be potential drug targets or biomarkers.

Drug Target Potential

The potential drug target for LINC02518 is the protein encoded by the gene USP4. USP4 has been shown to interact with LINC02518 and can promote its expression in cell culture. It is possible that USP4 could be a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

One approach to targeting USP4 is to use small molecules (SMCs) that can inhibit the activity of USP4. SMCs are a type of cell that have the ability to self-replicate and have been shown to be involved in a variety of cellular processes, including the regulation of gene expression. By inhibiting the activity of USP4 using SMCs, it may be possible to reduce the expression of the protein encoded by the gene USP4 and potentially treat a variety of diseases.

Biomarker Potential

LINC02518 is also a potential biomarker for a variety of diseases. Its expression has been shown to be elevated in a variety of tissues and cells, including the brain, heart, liver, and muscle. It is also highly expressed in the placenta, which is a critical site for fetal development and growth. These observations suggest that LINC02518 may be a useful biomarker for a variety of diseases, including neurodegenerative diseases, cancer, and cardiovascular disease.

Conclusion

LINC02518 is a long intergenic non-protein-coding RNA that has been identified using RNA-seq data. It has been shown to interact with several proteins that are involved in the regulation of gene expression, including USP4 and HNIP1. Its expression has also been shown to be elevated in a variety of tissues and cells, including the brain, heart, liver, and muscle. These observations suggest that LINC02518 may be a potential drug target or biomarker for a variety of diseases. Further research is needed to fully understand its function and potential applications.

Protein Name: Long Intergenic Non-protein Coding RNA 2518

The "LINC02518 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02518 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets